Chronic Wasting Disease (CWD) is a fatal neurological disease caused by infectious prions that is spreading undetected and largely uncontrolled across North America. CWD has now been detected throughout the United States and Canada, with infection rates reaching 50–80% of deer populations in some regions. Current management efforts cost an estimated $500 million annually, yet prions persist in the environment for decades, can become airborne, and accumulate in animal tissues. This growing threat poses significant risks to wildlife, livestock, agriculture, and human health. Current prion diagnostic tools are failing to keep up with the building threat.

Early detection is the only viable solution to controlling Chronic Wasting Disease. Priogen's proprietary seed amplification assays detect CWD prions years before clinical symptoms appear, enabling proactive intervention before further spread. Our integrated platform—combining proprietary hardware and reagents—delivers rapid, cost-effective, and versatile testing, empowering scalable surveillance and helping protect wildlife, agriculture, and public health. 

We have an innovative, diverse, and highly productive founding team that has worked together for 7 years, with support from advisors who collectively bring 75+ years of startup experience. Our core values are: 1) Function as a team, 2) Communicate openly and honestly, 3) Work with dedication, 4) Innovate with purpose, 5) Swift execution yields results.

We have established the foundation for a formidable corporation poised to lead the seed amplification assay industry. Our achievements include a solid revenue stream, an expanding customer base, numerous technological breakthroughs, functional prototypes, diverse product offerings, secured funding from venture capitalists and private investors, and a strategic, methodical rollout of services and technologies.